March 29, 2016
Gilead Sciences on Tuesday urged a California federal judge to reject Merck's request for millions in supplemental damages and pre-judgment interest on top of the $200 million that a jury said Gilead must pay for infringing two patents covering Gilead's hepatitis C drugs.
March 28, 2016
On the heels of last week's jury verdict that Gilead Sciences Inc. must pay Merck & Co. Inc. $200 million in a patent case over hepatitis C drugs, Merck asked a judge Monday to award it millions more in supplemental damages and prejudgment interest.
March 24, 2016
A California federal jury found on Thursday that Gilead Sciences must pay $200 million to rival Merck for infringing two patents covering a key ingredient used in Gilead's blockbuster hepatitis C drugs, an award that fell short of the $2 billion Merck had been seeking.
March 23, 2016
Merck obtained two patents covering a key ingredient used in hepatitis C drugs deceitfully and with "unclean hands," accused infringer Gilead told a California federal court Tuesday in an effort to defeat Merck's bid for $2 billion in damages.
March 22, 2016
A California federal jury said Tuesday that two patents held by Merck covering a key ingredient used in Gilead's blockbuster hepatitis C drugs were valid, setting the stage for a potential $2 billion windfall for Merck as the case heads to the damages phase.
February 02, 2016
Ahead of an upcoming jury trial, a California federal judge on Tuesday declined a request by Gilead Sciences to invalidate two patents held by rival Merck that were purportedly infringed by Gilead's hepatitis C drugs, finding that Merck presented enough evidence showing its patents were useful.
January 13, 2016
Gilead Sciences Inc. can’t take a look at work done by an attorney for a Merck & Co. Inc. subsidiary, a California magistrate judge has ruled, finding that Gilead hasn’t shown that the work product is relevant or necessary to the hepatitis C drug patent case.
December 10, 2015
Gilead Sciences Inc. urged a California federal judge Thursday to invalidate two Merck & Co Inc. patents on a hepatitis C drug, arguing that the patents fail to explain how the drug could be used to treat the sometimes fatal liver disease.